JPH11501915A - 皮膚炎の局部治療のためのgクラス免疫グロブリンの用法 - Google Patents
皮膚炎の局部治療のためのgクラス免疫グロブリンの用法Info
- Publication number
- JPH11501915A JPH11501915A JP8527431A JP52743196A JPH11501915A JP H11501915 A JPH11501915 A JP H11501915A JP 8527431 A JP8527431 A JP 8527431A JP 52743196 A JP52743196 A JP 52743196A JP H11501915 A JPH11501915 A JP H11501915A
- Authority
- JP
- Japan
- Prior art keywords
- dermatitis
- immunoglobulin
- pharmaceutical composition
- immunoglobulins
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 33
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 33
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims description 16
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 26
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 208000017520 skin disease Diseases 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 230000002458 infectious effect Effects 0.000 claims abstract description 7
- 238000001990 intravenous administration Methods 0.000 claims abstract description 7
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 5
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 5
- 210000003205 muscle Anatomy 0.000 claims abstract description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 4
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims abstract description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 4
- 206010000496 acne Diseases 0.000 claims abstract description 4
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 4
- 230000002538 fungal effect Effects 0.000 claims abstract description 4
- 206010021198 ichthyosis Diseases 0.000 claims abstract description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 4
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 230000001139 anti-pruritic effect Effects 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- -1 antifungals Substances 0.000 claims description 4
- 239000003908 antipruritic agent Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 229940008228 intravenous immunoglobulins Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 206010052891 Skin bacterial infection Diseases 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940121357 antivirals Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 230000003071 parasitic effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 229940028885 interleukin-4 Drugs 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 229940100602 interleukin-5 Drugs 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229940084388 gammar Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 241000428352 Amma Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.皮膚炎の局部治療剤を製造するためのGクラス免疫グロブリンの用法。 2.皮膚炎がアクネ、接触性皮膚炎、アトピー性皮膚炎、湿疹、魚鱗癬、乾癬 、丘疹鱗屑性皮膚障害(脂漏性皮膚炎、紅皮症)、真菌感染性皮膚炎、寄生虫感染 性皮膚炎、バクテリア感染性皮膚炎またはウイルス感染性皮膚炎である請求項1 記載の用法。 3.治療剤の形態が溶液、軟膏、クリーム、ゲルまたはリポソームである請求 項1または2記載の用法。 4.免疫グロブリンを抗生物質、抗ウイルス剤、抗真菌剤、ビタミン、抗炎症 剤、止痒剤および/または抗菌剤、不飽和脂肪酸、または免疫抑制剤と併用する 請求項1から3いずれかに記載の用法。 5.免疫グロブリンが静脈用免疫グロブリン(IVIGs)である請求項1から 4いずれかに記載の用法。 6.免疫グロブリンが筋肉用免疫グロブリン(IMIGs)である請求項1から 4いずれかに記載の用法。 7.皮膚炎の局部治療用薬剤組成物であって、皮膚炎を患う患者の炎症過程の 寛解を誘発するのに適した活性成分としてのGクラス免疫グロブリンおよび少な くとも1種の薬理学的に許容される賦形剤を含有する薬剤組成物。 8.皮膚炎がアクネ、接触性皮膚炎、アトピー性皮膚炎、湿疹、魚鱗癬、乾癬 、丘疹鱗屑性皮膚障害(脂漏性皮膚炎、紅皮症)、真菌感染性皮膚炎、寄生虫感染 性皮膚炎、バクテリア感染性皮膚炎またはウイルス感染性皮膚炎である請求項7 記載の薬剤組成物。 9.形態が溶液、軟膏、クリーム、ゲルまたはリポソームである請求項7また は8記載の薬剤組成物。 10.Gクラス免疫グロブリンを0.1〜25%含有する請求項9記載の薬剤組 成物。 11.抗生物質、抗ウイルス剤、抗真菌剤、ビタミン、抗炎症剤、止痒剤および /または抗菌剤、不飽和脂肪酸、または免疫抑制剤を含有する請求項7から10 いずれかに記載の薬剤組成物。 12.Gクラス免疫グロブリンが静脈用免疫グロブリン(IVIG)である請求項 7から11いずれかに記載の薬剤組成物。 13.Gクラス免疫グロブリンが筋肉用免疫グロブリン(IMIG)である請求項 7から11いずれかに記載の薬剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95A000154 | 1995-03-14 | ||
IT95RM000154A IT1278052B1 (it) | 1995-03-14 | 1995-03-14 | Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per |
PCT/IT1996/000047 WO1996028186A1 (en) | 1995-03-14 | 1996-03-12 | Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11501915A true JPH11501915A (ja) | 1999-02-16 |
JP3939346B2 JP3939346B2 (ja) | 2007-07-04 |
Family
ID=11403139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52743196A Expired - Fee Related JP3939346B2 (ja) | 1995-03-14 | 1996-03-12 | 皮膚炎の局部治療のためのgクラス免疫グロブリンの用法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6410019B1 (ja) |
EP (1) | EP0814837B2 (ja) |
JP (1) | JP3939346B2 (ja) |
KR (1) | KR19980702515A (ja) |
AT (1) | ATE228854T1 (ja) |
CA (1) | CA2213500C (ja) |
DE (1) | DE69625182T3 (ja) |
DK (1) | DK0814837T4 (ja) |
ES (1) | ES2187635T5 (ja) |
IT (1) | IT1278052B1 (ja) |
PT (1) | PT814837E (ja) |
WO (1) | WO1996028186A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059428A1 (en) * | 1993-02-26 | 2003-03-27 | Boris Skurkovich | Treatment of autoimmune diseases |
US7297480B2 (en) * | 2001-06-28 | 2007-11-20 | Dermtech International | Method for detection of melanoma |
US7183057B2 (en) * | 2004-03-31 | 2007-02-27 | Dermtech International | Tape stripping methods for analysis of skin disease and pathological skin state |
CA2686212A1 (en) * | 2007-05-04 | 2008-11-13 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
AU2009246180B2 (en) | 2008-05-14 | 2015-11-05 | Dermtech International | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
WO2010025341A2 (en) * | 2008-08-28 | 2010-03-04 | Dermtech International | Determining age ranges of skin samples |
EP3210618A1 (en) * | 2010-04-23 | 2017-08-30 | Probiotec Limited | Composition comprising lactoferrin and immunoglobulin for the treatment of eczema |
EP3752645A4 (en) | 2018-02-14 | 2022-04-13 | Dermtech, Inc. | NEW GENE CLASSIFIERS AND THEIR USES IN NON-MELANOMA SKIN CANCERS |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
US20240182552A1 (en) * | 2021-04-07 | 2024-06-06 | Ajou University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating immune dysregulation-related diseases comprising oxidized immunoglobulin as active ingredient |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2610854A1 (de) * | 1976-03-15 | 1977-09-22 | Biotest Serum Institut Gmbh | Galenische immunglobulinzubereitung |
ATE39842T1 (de) | 1983-06-07 | 1989-01-15 | Stolle Res & Dev | Desodorant das bakterielle antikoerper enthaelt. |
US5141742A (en) * | 1986-02-07 | 1992-08-25 | Oncogen | Vaccines against melanoma |
JPH03506024A (ja) * | 1988-07-22 | 1991-12-26 | シロス・タッチ・エルティーディー | 皮膚病の治療及び創傷の治癒を促進させる組成物及び方法 |
US5571511A (en) * | 1990-10-22 | 1996-11-05 | The U.S. Government | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
FR2669538B1 (fr) * | 1990-11-28 | 1995-03-03 | Fondation Nale Transfusion San | Utilisation d'immunoglobulines administrees localement dans le traitement des infections epitheliales. |
CA2153661A1 (en) * | 1993-01-12 | 1994-07-21 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity |
JP3193205B2 (ja) * | 1993-08-09 | 2001-07-30 | 日本臓器製薬株式会社 | 好酸球増多抑制剤 |
-
1995
- 1995-03-14 IT IT95RM000154A patent/IT1278052B1/it active IP Right Grant
-
1996
- 1996-03-12 PT PT96905988T patent/PT814837E/pt unknown
- 1996-03-12 KR KR1019970705915A patent/KR19980702515A/ko not_active Application Discontinuation
- 1996-03-12 JP JP52743196A patent/JP3939346B2/ja not_active Expired - Fee Related
- 1996-03-12 US US08/913,339 patent/US6410019B1/en not_active Expired - Fee Related
- 1996-03-12 DE DE69625182T patent/DE69625182T3/de not_active Expired - Lifetime
- 1996-03-12 ES ES96905988T patent/ES2187635T5/es not_active Expired - Lifetime
- 1996-03-12 AT AT96905988T patent/ATE228854T1/de not_active IP Right Cessation
- 1996-03-12 EP EP96905988A patent/EP0814837B2/en not_active Expired - Lifetime
- 1996-03-12 WO PCT/IT1996/000047 patent/WO1996028186A1/en not_active Application Discontinuation
- 1996-03-12 DK DK96905988T patent/DK0814837T4/da active
- 1996-03-12 CA CA2213500A patent/CA2213500C/en not_active Expired - Fee Related
-
2002
- 2002-05-20 US US10/147,855 patent/US7217416B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996028186A1 (en) | 1996-09-19 |
KR19980702515A (ko) | 1998-07-15 |
ITRM950154A1 (it) | 1996-09-14 |
EP0814837B1 (en) | 2002-12-04 |
US20020192276A1 (en) | 2002-12-19 |
JP3939346B2 (ja) | 2007-07-04 |
DE69625182T3 (de) | 2006-08-24 |
EP0814837A1 (en) | 1998-01-07 |
DE69625182D1 (de) | 2003-01-16 |
US6410019B1 (en) | 2002-06-25 |
ATE228854T1 (de) | 2002-12-15 |
DE69625182T2 (de) | 2003-11-20 |
EP0814837B2 (en) | 2006-02-22 |
DK0814837T3 (da) | 2003-03-31 |
PT814837E (pt) | 2003-04-30 |
CA2213500A1 (en) | 1996-09-19 |
ES2187635T3 (es) | 2003-06-16 |
ES2187635T5 (es) | 2006-09-01 |
ITRM950154A0 (it) | 1995-03-14 |
CA2213500C (en) | 2010-01-26 |
DK0814837T4 (da) | 2006-05-29 |
IT1278052B1 (it) | 1997-11-17 |
US7217416B2 (en) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Faergemann | Management of seborrheic dermatitis and pityriasis versicolor | |
Lister et al. | Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg) | |
DE68928857T2 (de) | Monoklonale Antikörper, die mit Cachectin reagieren | |
Hay et al. | Dandruff and seborrhoeic dermatitis: causes and management. | |
DE3642095C2 (de) | Monoclonale Antikörper, die kreuzreaktiv und kreuzprotektiv gegen P. AERUGINOSA-Serotypen sind | |
US5466675A (en) | Immunological activity of rhamnolipids | |
DE69511245T2 (de) | Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a | |
JP2001527046A (ja) | ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および/または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー | |
JPH11501915A (ja) | 皮膚炎の局部治療のためのgクラス免疫グロブリンの用法 | |
Fox et al. | Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects | |
DE3785967T2 (de) | Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung. | |
HIGGS et al. | Chronic muco‐cutaneous candidiasis: new approaches to treatment | |
HU211059B (en) | Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies | |
KR20150064091A (ko) | 정신의학적 병태의 치료법 | |
DE68911653T2 (de) | Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie. | |
DE3722098C2 (de) | Monoklonale Antikörper gegen Pseudomonas aeruginosa Flagellen | |
EP0648499B1 (en) | Composition for inhibiting IgE production | |
Rotaru et al. | Etiopathogenic and therapeutic considerations in atopic dermatitis | |
Freedman et al. | Influence of chloramphenicol and cetophenicol on antibody formation in mice | |
Karacic et al. | Effect of oral vs. parenteral cyclophosphamide on in vitro IgA and IgG production by murine Peyer's patches and cultured jejunal fragments | |
Traidl-Hoffmann et al. | Therapeutic management of atopic eczema | |
Zahedi | C-reactive protein interaction with macrophages: in vitro induction of tumor cytotoxicity, and characterization of C-reactive protein binding to macrophages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070313 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070328 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110406 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |